Literature DB >> 15006614

A new method for recombinant adeno-associated virus vector delivery to murine diaphragm.

Cathryn Mah1, Thomas J Fraites, Kerry O Cresawn, Irene Zolotukhin, Melissa A Lewis, Barry J Byrne.   

Abstract

Genetically modified mice are important models for evaluation of potential gene therapies for human diseases. However, their small size often precludes the use of clinically feasible methods for vector delivery, therefore, alternative methods must be used. We have developed a gel-based method for delivery of recombinant adeno-associated virus vectors to the mouse diaphragm, an important target organ for many myopathic diseases. We hypothesized that delivery of vectors in a viscous solution would increase transduction by providing a longer exposure time to target cells. We demonstrate that gel-mediated delivery of rAAV serotypes 1, 2, and 5 results in higher transduction efficiencies than free vectors alone when administered in vivo to mouse diaphragms. We further establish greater tropism of rAAV1 vectors for the diaphragm compared to serotypes 2 and 5. This report describes a novel method for efficient delivery of rAAV vectors to the mouse diaphragm and is the first demonstration of gene transfer to the diaphragm using recombinant adeno-associated virus vectors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15006614     DOI: 10.1016/j.ymthe.2004.01.006

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  16 in total

1.  Delivery of recombinant adeno-associated virus vectors to rat diaphragm muscle via direct intramuscular injection.

Authors:  Ashley J Smuder; Darin J Falk; Kurt J Sollanek; W Bradley Nelson; Scott K Powers
Journal:  Hum Gene Ther Methods       Date:  2013-10-11       Impact factor: 2.396

2.  Gel-mediated delivery of AAV1 vectors corrects ventilatory function in Pompe mice with established disease.

Authors:  Cathryn S Mah; Darin J Falk; Sean A Germain; Jeffry S Kelley; Melissa A Lewis; Denise A Cloutier; Lara R DeRuisseau; Thomas J Conlon; Kerry O Cresawn; Thomas J Fraites; Martha Campbell-Thompson; David D Fuller; Barry J Byrne
Journal:  Mol Ther       Date:  2010-01-26       Impact factor: 11.454

Review 3.  Pompe disease gene therapy.

Authors:  Barry J Byrne; Darin J Falk; Christina A Pacak; Sushrusha Nayak; Roland W Herzog; Melissa E Elder; Shelley W Collins; Thomas J Conlon; Nathalie Clement; Brian D Cleaver; Denise A Cloutier; Stacy L Porvasnik; Saleem Islam; Mai K Elmallah; Anatole Martin; Barbara K Smith; David D Fuller; Lee Ann Lawson; Cathryn S Mah
Journal:  Hum Mol Genet       Date:  2011-04-25       Impact factor: 6.150

Review 4.  Viral-mediated gene therapy for the muscular dystrophies: successes, limitations and recent advances.

Authors:  Guy L Odom; Paul Gregorevic; Jeffrey S Chamberlain
Journal:  Biochim Biophys Acta       Date:  2006-09-26

Review 5.  Pompe disease gene therapy: neural manifestations require consideration of CNS directed therapy.

Authors:  Barry J Byrne; David D Fuller; Barbara K Smith; Nathalie Clement; Kirsten Coleman; Brian Cleaver; Lauren Vaught; Darin J Falk; Angela McCall; Manuela Corti
Journal:  Ann Transl Med       Date:  2019-07

6.  Antibody formation and mannose-6-phosphate receptor expression impact the efficacy of muscle-specific transgene expression in murine Pompe disease.

Authors:  Baodong Sun; Songtao Li; Andrew Bird; Haiqing Yi; Alex Kemper; Beth L Thurberg; Dwight D Koeberl
Journal:  J Gene Med       Date:  2010-10-22       Impact factor: 4.565

7.  Neuroprotection by gene therapy targeting mutant SOD1 in individual pools of motor neurons does not translate into therapeutic benefit in fALS mice.

Authors:  Chris Towne; Veronica Setola; Bernard L Schneider; Patrick Aebischer
Journal:  Mol Ther       Date:  2010-11-23       Impact factor: 11.454

8.  Safety of Intradiaphragmatic Delivery of Adeno-Associated Virus-Mediated Alpha-Glucosidase (rAAV1-CMV-hGAA) Gene Therapy in Children Affected by Pompe Disease.

Authors:  Manuela Corti; Cristina Liberati; Barbara K Smith; Lee Ann Lawson; Ibrahim S Tuna; Thomas J Conlon; Kirsten E Coleman; Saleem Islam; Roland W Herzog; David D Fuller; Shelley W Collins; Barry J Byrne
Journal:  Hum Gene Ther Clin Dev       Date:  2017-12       Impact factor: 5.032

Review 9.  Adeno-associated virus-mediated gene therapy for metabolic myopathy.

Authors:  Cathryn S Mah; Meghan S Soustek; A Gary Todd; Angela McCall; Barbara K Smith; Manuela Corti; Darin J Falk; Barry J Byrne
Journal:  Hum Gene Ther       Date:  2013-11       Impact factor: 5.695

10.  Persistent expression of FLAG-tagged micro dystrophin in nonhuman primates following intramuscular and vascular delivery.

Authors:  Louise R Rodino-Klapac; Chrystal L Montgomery; William G Bremer; Kimberly M Shontz; Vinod Malik; Nancy Davis; Spencer Sprinkle; Katherine J Campbell; Zarife Sahenk; K Reed Clark; Christopher M Walker; Jerry R Mendell; Louis G Chicoine
Journal:  Mol Ther       Date:  2009-11-10       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.